Foamix Pharmaceuticals (NASDAQ:FOMX) received a $12.00 target price from research analysts at HC Wainwright in a research report issued on Friday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 91.08% from the stock’s current price.
A number of other analysts have also commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $8.00 target price on shares of Foamix Pharmaceuticals in a research report on Thursday, December 14th. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th.
Shares of Foamix Pharmaceuticals (FOMX) traded down $0.36 during trading on Friday, reaching $6.28. The company had a trading volume of 129,430 shares, compared to its average volume of 152,375. Foamix Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $11.11. The company has a market cap of $235.08, a price-to-earnings ratio of -4.79 and a beta of 1.62.
Several hedge funds and other institutional investors have recently made changes to their positions in FOMX. Bank of New York Mellon Corp boosted its stake in shares of Foamix Pharmaceuticals by 38.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 151,849 shares during the last quarter. AXA boosted its stake in shares of Foamix Pharmaceuticals by 14.1% in the 2nd quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock worth $4,374,000 after buying an additional 116,298 shares during the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Foamix Pharmaceuticals by 1.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after buying an additional 1,633 shares during the last quarter. PDT Partners LLC purchased a new position in shares of Foamix Pharmaceuticals in the 2nd quarter worth approximately $304,000. Finally, DAFNA Capital Management LLC boosted its stake in shares of Foamix Pharmaceuticals by 9.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock worth $1,650,000 after buying an additional 30,000 shares during the last quarter. Hedge funds and other institutional investors own 57.43% of the company’s stock.
WARNING: “Foamix Pharmaceuticals (FOMX) PT Set at $12.00 by HC Wainwright” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/foamix-pharmaceuticals-fomx-pt-set-at-12-00-by-hc-wainwright.html.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.